MannKind to Sponsor Juncos Hollinger Racing Driver Conor Daly
MannKind Corporation (Nasdaq:MNKD) announced today a continued partnership with Juncos Hollinger Racing (JHR) driver Conor Daly for the 2025 NTT INDYCAR SERIES season. Daly was diagnosed with Type 1 diabetes (T1D) when he was 14 and uses his racing career to help raise awareness about diabetes treatments and innovations. MannKind will be a primary sponsor on the No.76 at the Acura Grand Prix of Long Beach on April 13th.
“We’re thrilled to introduce a head-turning livery as Conor represents JHR this weekend through the streets of Long Beach,” said Dominic Marasco, President, Endocrine Business Unit of MannKind Corporation. “As part of an extended marketing partnership, we will work closely with Conor on a series of appearances to raise awareness about diabetes and innovative treatment options, aligning with key factors that are important with INDYCAR – speed and control.”
Conor Daly expressed his excitement for the partnership: “I’m really happy to keep working with MannKind. I’ve learned so much from a lot of the folks there and we have been able to tell an incredible story. They have helped me share my Type 1 diabetes (T1D) story with so many around the world, so to be able to represent Mannkind and tell my story living with Type 1 diabetes is really amazing.”
MannKind will also be a primary sponsor of the No.76 at the Chevrolet Detroit Grand Prix on June 1st and at World Wide Technology Raceway on June 15th. MannKind will continue to be an associate sponsor of Conor throughout the rest of the 2025 NTT INDYCAR SERIES schedule.
MannKind se une como sponsor oficial de Conor Daly
MannKind Corporation (MNKD) anunció hoy la continuación de su vínculo con el piloto de Juncos Hollinger Racing (JHR), Conor Daly, para la temporada 2025 de la NTT INDYCAR Series. Daly fue diagnosticado con diabetes tipo 1 cuando tenía 14 años y ha utilizado su carrera en el automovilismo para ayudar a fomentar conciencia sobre tratamientos e innovaciones en torno a la diabetes. MannKind será el patrocinador principal del auto Nº 76 en el Acura Grand Prix de Long Beach, el próximo 13 de abril.
La compañía destaca en el desarrollo y comercialización de productos terapéuticos inhalados innovadores y dispositivos para abordar necesidades médicas graves no satisfechas en personas con enfermedades endocrinas y pulmonares huérfanas.
“Estamos encantados de presentar un diseño llamativo mientras Conor representa a JHR este fin de semana en las calles de Long Beach”, precisó Dominic Marasco, Presidente de la Unidad de Negocios Endocrinos de MannKind Corporation. “Como parte de una asociación de marketing extendida, trabajaremos estrechamente con Conor en una serie de apariciones para aumentar la concientización sobre la diabetes y las opciones innovadoras de tratamiento, en línea con factores clave que también son fundamentales en INDYCAR: velocidad y control”.
Conor Daly expresó su entusiasmo por este acuerdo: “Estoy realmente feliz de seguir trabajando con MannKind. He aprendido muchísimo de varias personas allí y hemos podido contar una historia increíble. Me han ayudado a compartir mi historia con la diabetes tipo 1 con mucha gente en todo el mundo, así que poder representar a MannKind y contar cómo vivo con esta condición es realmente increíble”.
MannKind también será patrocinador principal del auto Nº 76 en el Chevrolet Detroit Grand Prix el 1 de junio y en el World Wide Technology Raceway el 15 de junio.
About MannKind Corporation
MannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of innovative inhaled therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases.
We are committed to using our formulation capabilities and device engineering prowess to lessen the burden of diseases such as diabetes, nontuberculous mycobacterial (NTM) lung disease, pulmonary fibrosis, and pulmonary hypertension. Our signature technologies – dry-powder formulations and inhalation devices – offer rapid and convenient delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation, depending on the target indication.
With a passionate team of Mannitarians collaborating nationwide, we are on a mission to give people control of their health and the freedom to live life.
Please visit mannkindcorp.com to learn more, and follow us on LinkedIn, Facebook, X or Instagram.
